Trial Profile
A study evaluating safety and efficacy of neoadjuvant everolimus in breast cancer patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2017
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Goserelin; Paclitaxel; Palbociclib; Pazopanib; Trametinib; Trastuzumab
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Apr 2017 New trial record
- 05 Apr 2017 Results (n=17) presented at the 108th Annual Meeting of the American Association for Cancer Research